 Irina Alimova
Concepts (208)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rhabdoid Tumor | 6 | 2025 | 102 | 2.470 |
Why?
| | SMARCB1 Protein | 2 | 2025 | 34 | 1.440 |
Why?
| | Medulloblastoma | 10 | 2022 | 215 | 1.430 |
Why?
| | Radiation Tolerance | 5 | 2022 | 103 | 1.280 |
Why?
| | Teratoma | 4 | 2022 | 124 | 1.100 |
Why?
| | Cerebellar Neoplasms | 7 | 2022 | 177 | 0.890 |
Why?
| | Sirtuin 2 | 1 | 2025 | 28 | 0.870 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2019 | 340 | 0.790 |
Why?
| | Gene Expression Regulation, Neoplastic | 8 | 2025 | 1457 | 0.760 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 67 | 0.690 |
Why?
| | Cell Proliferation | 14 | 2022 | 2529 | 0.680 |
Why?
| | Cell Cycle Proteins | 6 | 2022 | 633 | 0.640 |
Why?
| | Apoptosis | 13 | 2022 | 2454 | 0.610 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2019 | 169 | 0.600 |
Why?
| | Cell Cycle | 9 | 2016 | 600 | 0.560 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 536 | 0.530 |
Why?
| | Brain Neoplasms | 2 | 2025 | 1338 | 0.510 |
Why?
| | Cell Line, Tumor | 14 | 2025 | 3565 | 0.500 |
Why?
| | Cellular Senescence | 3 | 2019 | 229 | 0.500 |
Why?
| | Molecular Targeted Therapy | 2 | 2016 | 444 | 0.470 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2016 | 432 | 0.470 |
Why?
| | Polycomb Repressive Complex 2 | 2 | 2012 | 79 | 0.430 |
Why?
| | RNA, Small Interfering | 2 | 2012 | 643 | 0.380 |
Why?
| | Neoplastic Stem Cells | 2 | 2014 | 409 | 0.350 |
Why?
| | Biomarkers, Tumor | 3 | 2016 | 1339 | 0.310 |
Why?
| | Metformin | 2 | 2009 | 329 | 0.280 |
Why?
| | Transcription Factors | 2 | 2014 | 1747 | 0.260 |
Why?
| | Proto-Oncogene Proteins | 4 | 2022 | 627 | 0.260 |
Why?
| | Cell Differentiation | 5 | 2025 | 2054 | 0.260 |
Why?
| | Cerebellum | 3 | 2012 | 227 | 0.240 |
Why?
| | Blotting, Western | 6 | 2014 | 1186 | 0.230 |
Why?
| | Tumor Cells, Cultured | 5 | 2014 | 891 | 0.220 |
Why?
| | DNA-Binding Proteins | 1 | 2012 | 1488 | 0.220 |
Why?
| | Radiation-Sensitizing Agents | 2 | 2016 | 43 | 0.210 |
Why?
| | Nuclear Proteins | 3 | 2014 | 745 | 0.200 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 2 | 2012 | 55 | 0.180 |
Why?
| | Azepines | 3 | 2019 | 105 | 0.180 |
Why?
| | Polycomb Repressive Complex 1 | 2 | 2020 | 66 | 0.170 |
Why?
| | Spheroids, Cellular | 2 | 2012 | 82 | 0.170 |
Why?
| | Mice | 14 | 2025 | 18491 | 0.170 |
Why?
| | Pyrazoles | 4 | 2022 | 518 | 0.170 |
Why?
| | Mice, Nude | 3 | 2019 | 680 | 0.160 |
Why?
| | Aging | 4 | 2020 | 1992 | 0.160 |
Why?
| | Triazoles | 2 | 2019 | 191 | 0.150 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2019 | 939 | 0.150 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2016 | 751 | 0.150 |
Why?
| | Quinazolines | 2 | 2022 | 266 | 0.150 |
Why?
| | Breast Neoplasms | 2 | 2009 | 2420 | 0.150 |
Why?
| | Hypoglycemic Agents | 1 | 2009 | 1415 | 0.140 |
Why?
| | Pteridines | 2 | 2016 | 22 | 0.140 |
Why?
| | Mammary Neoplasms, Animal | 3 | 2003 | 35 | 0.140 |
Why?
| | Cell Self Renewal | 1 | 2019 | 52 | 0.140 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2019 | 144 | 0.130 |
Why?
| | Chromatin | 2 | 2020 | 561 | 0.130 |
Why?
| | RNA, Messenger | 5 | 2014 | 2812 | 0.130 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2014 | 337 | 0.130 |
Why?
| | Antineoplastic Agents | 4 | 2022 | 2231 | 0.130 |
Why?
| | Humans | 22 | 2025 | 147293 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2014 | 980 | 0.130 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2016 | 23 | 0.120 |
Why?
| | Checkpoint Kinase 1 | 1 | 2016 | 27 | 0.120 |
Why?
| | Animals | 14 | 2025 | 38410 | 0.120 |
Why?
| | Glioma | 2 | 2020 | 432 | 0.120 |
Why?
| | Cyclin-Dependent Kinase 6 | 2 | 2012 | 49 | 0.110 |
Why?
| | Mitosis | 1 | 2016 | 194 | 0.110 |
Why?
| | MicroRNAs | 2 | 2012 | 694 | 0.110 |
Why?
| | Radiation, Ionizing | 2 | 2012 | 86 | 0.110 |
Why?
| | HeLa Cells | 1 | 2016 | 633 | 0.110 |
Why?
| | Longevity | 3 | 2011 | 178 | 0.100 |
Why?
| | Mammary Neoplasms, Experimental | 2 | 2003 | 62 | 0.090 |
Why?
| | Central Nervous System Neoplasms | 2 | 2012 | 178 | 0.090 |
Why?
| | Colony-Forming Units Assay | 1 | 2012 | 95 | 0.090 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 200 | 0.090 |
Why?
| | Luciferases | 1 | 2012 | 155 | 0.090 |
Why?
| | Histones | 2 | 2020 | 672 | 0.090 |
Why?
| | Melatonin | 2 | 2003 | 164 | 0.090 |
Why?
| | Colorado | 1 | 2022 | 4591 | 0.090 |
Why?
| | Gene Expression Profiling | 3 | 2014 | 1794 | 0.090 |
Why?
| | DNA Copy Number Variations | 1 | 2012 | 190 | 0.080 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2011 | 196 | 0.080 |
Why?
| | Oligopeptides | 2 | 2003 | 267 | 0.080 |
Why?
| | Drug Design | 1 | 2011 | 177 | 0.080 |
Why?
| | Repressor Proteins | 2 | 2012 | 429 | 0.080 |
Why?
| | Adenosine | 1 | 2012 | 255 | 0.080 |
Why?
| | Intracellular Space | 1 | 2010 | 64 | 0.080 |
Why?
| | Child | 6 | 2022 | 22979 | 0.080 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2011 | 219 | 0.080 |
Why?
| | Receptors, Retinoic Acid | 1 | 2009 | 44 | 0.080 |
Why?
| | Neoplasm Proteins | 1 | 2012 | 445 | 0.070 |
Why?
| | Tretinoin | 1 | 2009 | 125 | 0.070 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2009 | 122 | 0.070 |
Why?
| | Enzyme Inhibitors | 4 | 2012 | 822 | 0.070 |
Why?
| | Flow Cytometry | 1 | 2012 | 1172 | 0.070 |
Why?
| | Cell Survival | 3 | 2016 | 1111 | 0.070 |
Why?
| | Reactive Oxygen Species | 1 | 2010 | 616 | 0.060 |
Why?
| | DNA Methylation | 1 | 2012 | 722 | 0.060 |
Why?
| | Receptors, Estrogen | 1 | 2009 | 406 | 0.060 |
Why?
| | Piperazines | 2 | 2022 | 375 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2012 | 3660 | 0.050 |
Why?
| | Signal Transduction | 4 | 2012 | 5272 | 0.050 |
Why?
| | Delta Sleep-Inducing Peptide | 1 | 2003 | 1 | 0.050 |
Why?
| | Genes, erbB-2 | 1 | 2003 | 32 | 0.050 |
Why?
| | Adolescent | 2 | 2012 | 22825 | 0.050 |
Why?
| | Child, Preschool | 5 | 2020 | 12016 | 0.050 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 44 | 0.040 |
Why?
| | Neoplasms, Experimental | 1 | 2003 | 167 | 0.040 |
Why?
| | Female | 11 | 2020 | 80076 | 0.040 |
Why?
| | Ovary | 1 | 2003 | 236 | 0.040 |
Why?
| | Carcinoma | 1 | 2003 | 231 | 0.040 |
Why?
| | Neural Stem Cells | 2 | 2012 | 168 | 0.040 |
Why?
| | Epigenomics | 1 | 2020 | 125 | 0.040 |
Why?
| | Brain Stem Neoplasms | 1 | 2020 | 87 | 0.040 |
Why?
| | Astrocytoma | 1 | 2020 | 131 | 0.040 |
Why?
| | Pyrimidines | 2 | 2014 | 532 | 0.040 |
Why?
| | Antioxidants | 1 | 2003 | 550 | 0.040 |
Why?
| | Body Weight | 4 | 2003 | 976 | 0.030 |
Why?
| | Lysine | 1 | 2020 | 305 | 0.030 |
Why?
| | Pyridines | 2 | 2012 | 610 | 0.030 |
Why?
| | Benzodiazepinones | 1 | 2016 | 18 | 0.030 |
Why?
| | Genes, myc | 1 | 2016 | 51 | 0.030 |
Why?
| | Prognosis | 2 | 2016 | 4383 | 0.030 |
Why?
| | Urea | 1 | 2016 | 85 | 0.030 |
Why?
| | Thiophenes | 1 | 2016 | 117 | 0.030 |
Why?
| | Adenocarcinoma | 1 | 2003 | 928 | 0.030 |
Why?
| | Biomarkers | 2 | 2003 | 4351 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 779 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 347 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2012 | 2030 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 975 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 1166 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 780 | 0.020 |
Why?
| | DNA Damage | 1 | 2016 | 440 | 0.020 |
Why?
| | Up-Regulation | 1 | 2016 | 848 | 0.020 |
Why?
| | Mice, Transgenic | 3 | 2003 | 2197 | 0.020 |
Why?
| | Pyrimidinones | 1 | 2014 | 125 | 0.020 |
Why?
| | Estrus | 2 | 2003 | 16 | 0.020 |
Why?
| | Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2012 | 27 | 0.020 |
Why?
| | Cathepsin B | 1 | 2012 | 17 | 0.020 |
Why?
| | Argonaute Proteins | 1 | 2012 | 32 | 0.020 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2012 | 141 | 0.020 |
Why?
| | Homozygote | 2 | 2003 | 199 | 0.020 |
Why?
| | Mice, Inbred Strains | 2 | 2003 | 397 | 0.020 |
Why?
| | Chromosome Aberrations | 2 | 2003 | 168 | 0.020 |
Why?
| | Aurora Kinases | 1 | 2012 | 28 | 0.020 |
Why?
| | 3' Untranslated Regions | 1 | 2012 | 149 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2012 | 117 | 0.020 |
Why?
| | Body Temperature | 2 | 2003 | 229 | 0.020 |
Why?
| | Aurora Kinase A | 1 | 2012 | 61 | 0.020 |
Why?
| | Genome, Human | 1 | 2014 | 426 | 0.020 |
Why?
| | Tubulin | 1 | 2012 | 146 | 0.020 |
Why?
| | Anticarcinogenic Agents | 1 | 2011 | 63 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 512 | 0.020 |
Why?
| | Acetylation | 1 | 2011 | 262 | 0.020 |
Why?
| | RNA Interference | 1 | 2012 | 477 | 0.020 |
Why?
| | Benzamides | 1 | 2011 | 227 | 0.020 |
Why?
| | Eating | 2 | 2003 | 387 | 0.020 |
Why?
| | Retinoic Acid Receptor alpha | 1 | 2009 | 16 | 0.020 |
Why?
| | Superoxides | 1 | 2010 | 199 | 0.020 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2009 | 88 | 0.020 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2009 | 139 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2012 | 539 | 0.020 |
Why?
| | Mutation | 1 | 2020 | 4130 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 2110 | 0.020 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2009 | 88 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1281 | 0.020 |
Why?
| | Genomics | 1 | 2014 | 839 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2012 | 731 | 0.020 |
Why?
| | Caspases | 1 | 2009 | 233 | 0.020 |
Why?
| | Cell Movement | 1 | 2012 | 966 | 0.020 |
Why?
| | Down-Regulation | 1 | 2010 | 618 | 0.020 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2009 | 192 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2014 | 984 | 0.020 |
Why?
| | Neoplasms | 1 | 2003 | 2946 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2175 | 0.020 |
Why?
| | Feeding Behavior | 2 | 2003 | 693 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 2001 | 0.010 |
Why?
| | Incidence | 2 | 2003 | 2954 | 0.010 |
Why?
| | RNA | 1 | 2012 | 916 | 0.010 |
Why?
| | Phosphorylation | 1 | 2009 | 1721 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2009 | 1253 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3216 | 0.010 |
Why?
| | Male | 3 | 2020 | 73950 | 0.010 |
Why?
| | Protein Binding | 1 | 2009 | 2249 | 0.010 |
Why?
| | Estrous Cycle | 1 | 2003 | 22 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2009 | 1456 | 0.010 |
Why?
| | Rats | 1 | 2011 | 5613 | 0.010 |
Why?
| | Pregnancy, Animal | 1 | 2003 | 51 | 0.010 |
Why?
| | Photoperiod | 1 | 2003 | 55 | 0.010 |
Why?
| | Dipeptides | 1 | 2002 | 56 | 0.010 |
Why?
| | Ovariectomy | 1 | 2003 | 166 | 0.010 |
Why?
| | Life Expectancy | 1 | 2003 | 73 | 0.010 |
Why?
| | Random Allocation | 1 | 2003 | 366 | 0.010 |
Why?
| | Polycystic Kidney Diseases | 1 | 2003 | 82 | 0.010 |
Why?
| | Time Factors | 2 | 2003 | 7173 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 2003 | 325 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 6099 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4604 | 0.010 |
Why?
| | Leukemia | 1 | 2003 | 247 | 0.010 |
Why?
| | Cell Division | 1 | 2002 | 758 | 0.010 |
Why?
| | Survival Analysis | 1 | 2003 | 1386 | 0.010 |
Why?
| | Models, Theoretical | 1 | 2003 | 563 | 0.010 |
Why?
| | Models, Statistical | 1 | 2003 | 677 | 0.010 |
Why?
| | Brain | 1 | 2010 | 3009 | 0.010 |
Why?
| | Age Factors | 1 | 2003 | 3372 | 0.010 |
Why?
| | Disease Progression | 1 | 2003 | 2890 | 0.010 |
Why?
| | Pregnancy | 1 | 2003 | 7274 | 0.000 |
Why?
| | Lung Neoplasms | 1 | 2002 | 2679 | 0.000 |
Why?
| | Risk Factors | 1 | 2003 | 11017 | 0.000 |
Why?
|
|
Alimova's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|